Core Insights - The study published in Nature Medicine highlights the significant effects of semaglutide on the circulating proteome, revealing new biological mechanisms and potential health benefits beyond obesity [2][3] - Standard BioTools' SomaScan platform played a crucial role in this research, demonstrating the power of advanced proteomic analysis in drug development and precision medicine [3][4] Company Insights - Standard BioTools Inc. is focused on providing next-generation technologies that enhance biomedical research, aiming to accelerate the development of effective therapies [7] - The SomaScan technology offers unique advantages, including reliable and reproducible results, which are critical for advancing precision medicine [4][6] Industry Insights - The rising global obesity rates have led to increased interest in therapies targeting obesity and its associated health risks, with GLP-1 drugs, including semaglutide, becoming a leading option in the pharmaceutical market [3][6] - The study's findings suggest that proteomics can facilitate the accelerated clinical development of novel drug indications, potentially transforming treatment approaches for various health conditions [6]

Core Viewpoint - Standard BioTools Inc. will present at the 43rd Annual J.P. Morgan Healthcare Conference, highlighting its role in advancing biomedical research and technologies [1][2]. Company Overview - Standard BioTools Inc. (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a leading provider of next-generation technologies aimed at accelerating the development of medicines [3]. - The company offers proprietary technologies such as SomaScan, mass cytometry, and microfluidics, which provide reliable insights into health and disease [3]. - Standard BioTools collaborates with various sectors, including academic, government, pharmaceutical, and biotechnology, focusing on critical areas in translational and clinical research like oncology and immunology [3]. Event Details - The corporate presentation by Dr. Michael Egholm is scheduled for January 16, 2024, at 9:45 a.m. PT, with a live audio webcast available for investors [2]. - A recording of the presentation will be archived on the company's Investor Relations page [2].

Core Insights - Standard BioTools Inc. has appointed Alex Kim as Chief Financial Officer, effective November 11, 2024, bringing nearly 30 years of experience in financial and operational roles within the healthcare and life sciences sectors [1][2]. Company Overview - Standard BioTools Inc., previously known as Fluidigm Corporation, is a leading provider of next-generation technologies that assist biomedical researchers in developing medicines more efficiently. The company utilizes proprietary mass cytometry and microfluidics technologies to deliver reliable insights in health and disease [4]. Leadership and Experience - Alex Kim, co-founder of Standard BioTools, has a strong background in healthcare, having held significant positions at Milliken's Healthcare Division, Pall Corporation, and Danaher Corporation, where he completed over 40 transactions focused on healthcare and medical technology [2][3]. - Michael Egholm, President and CEO of Standard BioTools, expressed confidence in Kim's appointment, highlighting his deep understanding of the business and his role in shaping the company's strategic and financial plans [2]. Strategic Focus - Kim emphasized the company's commitment to operational excellence and achieving financial targets and long-term growth objectives, indicating a strong momentum moving forward [3].

Revenue Growth and Performance - Total revenue for Q3 2024 increased to $44.969 million, up from $25.367 million in Q3 2023, driven by growth in product and services revenue[10] - Product revenue for Q3 2024 reached $19.593 million, compared to $18.711 million in Q3 2023, reflecting steady growth[10] - Services revenue surged to $24.438 million in Q3 2024, a significant increase from $6.566 million in Q3 2023[10] - Revenue for the three months ended September 30, 2024 was $44.969 million, compared to $25.367 million in the same period in 2023, representing a 77.3% increase[56][58] - Product revenue for the three months ended September 30, 2024 was $19.593 million, with consumables contributing $14.007 million and instruments $5.586 million[58] - Service revenue for the three months ended September 30, 2024 was $24.438 million, driven by $18.247 million from lab services[58] - Revenue from the Americas region was $23.751 million for the three months ended September 30, 2024, representing 52.8% of total revenue[59] - Total revenue for the three months ended September 30, 2024, was $44.969 million, with Proteomics contributing $34.565 million and Genomics contributing $10.404 million[130] - Total revenue for the nine months ended September 30, 2024, was $127.714 million, with Proteomics contributing $98.954 million and Genomics contributing $28.760 million[130] Profitability and Losses - Gross profit for Q3 2024 improved to $23.261 million, up from $11.154 million in Q3 2023, indicating better cost management[10] - Net loss for Q3 2024 was $26.938 million, compared to a net loss of $20.997 million in Q3 2023[10] - Comprehensive loss for Q3 2024 was $26.847 million, slightly better than the $21.395 million loss in Q3 2023[12] - Net loss for the quarter ending September 30, 2024, is $(26,938)[14] - Net loss for the quarter ending September 30, 2023, is $(20,997)[15] - Net loss for the nine months ended September 30, 2024, was $104.8 million, compared to $54.9 million in the same period in 2023[17] - Net loss for the three months ended September 30, 2024 was $26.938 million, an improvement from the $41.204 million loss in the same period in 2023[56] - SomaLogic contributed $61.5 million in revenue and $30.6 million in loss for the period from January 6, 2024 to September 30, 2024[57] - Total loss from operations for the three months ended September 30, 2024, was $31.718 million, with Proteomics contributing a loss of $10.210 million and Genomics contributing a profit of $1.925 million[130] - Total loss from operations for the nine months ended September 30, 2024, was $142.419 million, with Proteomics contributing a loss of $48.485 million and Genomics contributing a profit of $2.681 million[130] - Net loss per share for the nine months ended September 30, 2024: $(0.44), compared to $(0.69) for the same period in 2023[123] Expenses and Investments - Research and development expenses increased to $13.156 million in Q3 2024, up from $6.370 million in Q3 2023, reflecting higher investment in innovation[10] - Selling, general, and administrative expenses rose to $34.403 million in Q3 2024, compared to $22.292 million in Q3 2023, due to expanded operations[10] - Transaction and integration expenses for Q3 2024 were $5.079 million, up from $1.666 million in Q3 2023, primarily due to merger-related costs[10] - Stock-based compensation expense for the quarter ending September 30, 2024, is $5,921[14] - Stock-based compensation expense for the quarter ending September 30, 2023, is $3,386[15] - Stock-based compensation expense for the nine months ended September 30, 2024: $24.3 million, compared to $9.6 million for the same period in 2023[120] - Stock-based compensation expense due to the acceleration of awards for certain SomaLogic executives in connection with the Merger: $6.2 million for the nine months ended September 30, 2024[114] - The Company recognized restructuring charges of $2.3 million and $12.4 million during the three and nine months ended September 30, 2024, respectively, related to a restructuring plan implemented after the Merger[131] - The Company's restructuring and related liabilities for the nine months ended September 30, 2024, included $9.522 million in severance and other employee-related benefits and $2.108 million in facility costs[132] - Income tax expense for the nine months ended September 30, 2024: $0.3 million, compared to $0.6 million for the same period in 2023[127] Merger and Integration - The company completed its merger with SomaLogic, Inc. in January 2024, which is expected to drive future growth and integration benefits[4] - Equity consideration transferred in connection with the Merger included 26,367 shares of common stock[16] - Cash and restricted cash acquired in the Merger was $280.0 million[17] - Equity consideration transferred in connection with the Merger was $444.2 million[17] - The Merger with SomaLogic resulted in a total consideration of $444.2 million, including $419.2 million in common stock and $26.9 million in replacement equity awards[45][46] - The Merger resulted in a bargain purchase gain of $25.2 million due to a rapid decline in the Company's common stock price post-announcement[49] - The Company reduced its workforce by approximately 10% of its total workforce as part of the Strategic Reorganization, with the majority of employees separating by July 2024[131] - Eli Casdin, a member of the Company's board of directors, may be deemed to have beneficially received 26,515,248 shares of common stock in the Merger, including shares issuable upon the vesting of RSUs and exercise of options and warrants[134] Cash Flow and Financial Position - Net cash used in operating activities for the nine months ended September 30, 2024, was $129.4 million, compared to $29.2 million in the same period in 2023[17] - Net cash provided by investing activities for the nine months ended September 30, 2024, was $337.4 million, compared to $33.4 million in the same period in 2023[17] - Net cash used in financing activities for the nine months ended September 30, 2024, was $48.1 million, compared to $5.8 million in the same period in 2023[17] - Cash, cash equivalents, and restricted cash at the end of the period were $211.9 million, compared to $80.5 million at the end of the same period in 2023[17] - Cash, cash equivalents and restricted cash totaled $211.938 million as of September 30, 2024, up from $52.499 million at December 31, 2023[73] - Total debt decreased from $63,513 thousand in December 2023 to $55,212 thousand in September 2024, primarily due to the repayment of the Term Loan Facility[86][88] - The company received $34.0 million from the NIH for COVID-19 test production capacity expansion, with $22.2 million used for capital expenditures in its Singapore facility[82] Assets and Liabilities - Total Stockholders' Equity (Deficit) as of September 30, 2024, is $489,333[14] - Accumulated Deficit as of September 30, 2024, is $(1,151,579)[14] - Total Stockholders' Equity (Deficit) as of September 30, 2023, is $(131,720)[15] - Accumulated Deficit as of September 30, 2023, is $(980,976)[15] - Trade receivables increased from $19,972 thousand in December 2023 to $35,337 thousand in September 2024, reflecting a growth of 76.9%[75] - Total inventory surged from $20,533 thousand in December 2023 to $60,593 thousand in September 2024, a 195.2% increase, driven by raw materials growth from $12,140 thousand to $49,953 thousand[76] - The company recorded charges for excess and obsolete inventory of $0.1 million for the three months ended September 30, 2024, compared to $0.4 million in the same period in 2023[77] - Property and equipment, net increased from $24,187 thousand in December 2023 to $41,982 thousand in September 2024, with laboratory and manufacturing equipment growing from $35,563 thousand to $59,785 thousand[78] - Accrued liabilities rose from $21,019 thousand in December 2023 to $31,686 thousand in September 2024, with accrued compensation and related benefits increasing from $12,052 thousand to $14,390 thousand[79] - The company has open purchase commitments totaling $16.2 million as of September 30, 2024[93] - Under the Illumina Agreement, the company has a minimum purchase commitment of $6.9 million over three years with IDT for contract manufacturing[94] - The company has entered into several license and patent agreements, paying annual fees and royalties based on net sales, but future payments are indeterminable and not expected to be material in any year[95] - The company settled litigation with former stockholders, repurchasing 1.84 million shares at $2.40 per share and paying $1.8 million in cash, recognizing a $0.6 million litigation loss[99] - As of September 30, 2024, the company's total assets measured at fair value were $340.91 million, including $185.23 million in cash equivalents and $155.68 million in short-term investments[101] - The fair value of warrant liabilities decreased by $474,000 to $432,000 as of September 30, 2024, using Level 3 inputs for valuation[104][105] - The company's available-for-sale securities had unrealized gains of $348,000 as of September 30, 2024, with no securities in an unrealized loss position for over 12 months[103] - Total common stock reserved for future issuance as of September 30, 2024: 40,228 thousand shares for options, 14,436 thousand shares for restricted stock, and 25,419 thousand shares available for future issuance[111] - Unrecognized stock-based compensation expense related to outstanding unvested RSUs as of September 30, 2024: $29.8 million, expected to be recognized over a weighted-average period of 3.1 years[115] - Aggregate unrecognized compensation costs related to outstanding unvested options as of September 30, 2024: $22.5 million, expected to be recognized over a weighted-average period of 2.6 years[117] - Balance of restricted stock units (RSUs) as of September 30, 2024: 14,436 thousand units, with a weighted-average fair value per unit of $2.24[115] - Balance of stock options as of September 30, 2024: 40,228 thousand options, with a weighted-average exercise price of $4.26 and a weighted-average remaining contractual life of 6.2 years[116] - Total intrinsic value of options exercised during the nine months ended September 30, 2024: $0.6 million[117] Revenue Recognition and Contracts - Revenue recognition is based on the transaction price, which reflects the consideration the Company expects to receive in exchange for products or services[31] - Product revenue is recognized at the point of control transfer, either at shipment or customer facility arrival, with invoices due in 30 to 60 days[34] - SomaScan® equipment bundle revenue is recognized over time based on progress toward performance obligations, using an input method of costs incurred[34] - Lab services revenue is recognized upon delivery of analysis data or reports, with SomaScan® services sold at a fixed price per sample without discounts[35] - Field services revenue is recognized over time using a time-elapsed measure, with invoices issued in advance and payments collected reported as deferred revenue[36] - Collaboration revenue is recognized as obligations are satisfied, with payments for R&D activities analogized to ASC 606[38] - License and royalty revenue is recognized when the license is transferred and the customer can benefit, with sales-based royalties recognized upon related sales[39] - Grant revenue is recognized when conditions are met and remaining performance obligations are perfunctory, not accounted for under ASC 606[40] - The Illumina Agreement has a total transaction price of $158.4 million, with $127.9 million in expected royalties from 2025 through 2032[62] - Deferred revenue as of September 30, 2024 was $46.118 million, with $30.012 million related to the Illumina Agreement[65] Depreciation and Amortization - The Company's total depreciation and amortization for the three months ended September 30, 2024, was $3.858 million, with Proteomics contributing $1.940 million and Genomics contributing $378 million[130] - The Company's total depreciation and amortization for the nine months ended September 30, 2024, was $12.908 million, with Proteomics contributing $7.193 million and Genomics contributing $1.125 million[130] - Future expected amortization expense of acquired intangible assets is $23.367 million, with $11.280 million expected after 2028[72] Legal and Compliance - The company may face additional costs and liabilities post-merger, including legal and compliance matters, which could impact its financial condition[100] - The company resolved fee disputes with all but two stockholders' counsel regarding demands for book and record inspections[99] Share Repurchase and Equity Transactions - The company repurchased 13.6 million shares of common stock for $36.1 million under the 2024 Share Repurchase Program[110] - The company exchanged Series B Preferred Stock for 92.93 million shares of common stock, resulting in a $46.0 million difference recognized in accumulated deficit[107][109] - The company filed a registration statement for the resale of 105.12 million shares of common stock, including shares from the Series B Preferred Stock exchange[108] Warrants and Liabilities - The Company assumed 5,519,991 Public Warrants and 5,013,333 Private Placement Warrants, now identical and classified as liabilities[41][42] - The fair value of warrant liabilities decreased by $474,000 to $432,000 as of September 30, 2024, using Level 3 inputs for valuation[104][105] Lease and Facility Costs - Lease costs for operating leases increased from $6,005 thousand for the nine months ended September 30, 2023, to $7,484 thousand for the same period in 2024[90]

Standard BioTools Inc. (NASDAQ:LAB) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants David Holmes - IR Michael Egholm - President & CEO Alex Kim - Chief Operating Officer & Interim-CFO Conference Call Participants Matt Stanton - Jefferies Operator Good day and welcome to the Standard BioTools Inc Third Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode. After today’s presentation, There will be an opportunity to ask questions. [Opera ...

Standard BioTools (LAB) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 37.50%. A quarter ago, it was expected that this company that makes equipment to control fluids would post a loss of $0.06 per share when it actually produced a loss of $0.08, delivering a surprise of -33.33%. Over the l ...

Exhibit 99.1 Standard BioTools Reports Third Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., October 30, 2024 -- Standard BioTools Inc. (NASDAQ: LAB) (the "Company") today announced unaudited interim financial results for the third quarter ended September 30, 2024. Recent Highlights: • Reported third quarter 2024 revenue of $45 million • Ongoing merger cost synergy realization delivered 50% adjusted EBITDA improvement and 35% net loss improvement year-over-year • Operationalized approximately $8 ...

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the "Company") today announced unaudited interim financial results for the third quarter ended September 30, 2024. Recent Highlights: Reported third quarter 2024 revenue of $45 million Ongoing merger cost synergy realization delivered 50% adjusted EBITDA improvement and 35% net loss improvement year-over-year Operationalized approximately $80 million in merger synergies, expected to be fully realized in 2025 ...

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the market. The Company's management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on October 30, 2024, to discuss third quarter 2024 financial results and operational progress. A press release including the financial results will be publicly distributed before t ...

MEXICO CITY, Sept. 10, 2024 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred ...